Drug companies have formed a new group to present lawmakers with research on what the industry sees as the negative impacts ...

Federal judges in Texas and Connecticut on Thursday ruled against arguments challenging the constitutionality of the Medicare ...

The drug industry’s top lobbying group is appealing its latest loss in its challenge to Medicare’s Drug Price Negotiation ...

Three federal courts reject legal challenges to Medicare drug price negotiation Judges side with government in cases filed by ...

Pharmaceutical companies were dealt back-to-back blows over the last 24 hours in their fight against the Biden-era Medicare ...

All other drugs listed cost the program under $2 billion. Medicare Part D spent the least on Otezla at $995 million, with 31,000 enrollees who used that medication, according to the fact sheet.

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, ...

Little-known provisions in the Big Beautiful Bill lobbied by industry will cost Medicare billions in missed savings.

Medicare drug price negotiation is still relatively new. Until the 2022 passage of the Inflation Reduction Act, Medicare part D, which covers more than 50 million seniors, didn't have the ...

WASHINGTON -- The Biden administration unveiled Tuesday the names of the first 10 drugs subject to price negotiations in Medicare, including blood thinners and diabetes medications. They are: ...

More than half of the drugs – 13 out of 25 – in the first and second rounds of negotiations would have been ineligible at the time they were selected if the discrepancy between small-molecule ...

Medicare drug price negotiation is still relatively new. Until the 2022 passage of the Inflation Reduction Act, Medicare part D, which covers more than 50 million seniors, didn't have the ...